Show simple item record

dc.contributor.authorAcerini, Carlo L
dc.contributor.authorSegal, David
dc.contributor.authorCriseno, Sherwin
dc.contributor.authorTakasawa, Kei
dc.contributor.authorNedjatian, Navid
dc.contributor.authorRöhrich, Sebastian
dc.contributor.authorMaghnie, Mohamad
dc.date.accessioned2018-12-12T00:31:33Z
dc.date.available2018-12-12T00:31:33Z
dc.date.issued2018
dc.identifier.issn1664-2392
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/286720
dc.description.abstractSeveral studies have shown that adherence to growth hormone therapy (GHT) is not optimal. There are several reasons why patients may not fully adhere to their treatment regimen and this may have implications on treatment success, patient outcomes and healthcare spending and resourcing. A change in healthcare practices, from a physician paternalistic to a more patient autonomous approach to healthcare, has encouraged a greater onus on a shared decision-making (SDM) process whereby patients are actively encouraged to participate in their own healthcare decisions. There is growing evidence to suggest that SDM may facilitate patient adherence to GHT. Improved adherence to therapy in this way may consequently positively impact treatment outcomes for patients. Whilst SDM is widely regarded as a healthcare imperative, there is little guidance on how it should be best implemented. Despite this, there are many opportunities for the implementation of SDM during the treatment journey of a patient with a GH-related disorder. Barriers to the successful practice of SDM within the clinic may include poor patient education surrounding their condition and treatment options, limited healthcare professional time, lack of support from clinics to use SDM, and healthcare resourcing restrictions. Here we discuss the opportunities for the implementation of SDM and the barriers that challenge its effective use within the clinic. We also review some of the potential solutions to overcome these challenges that may prove key to effective patient participation in treatment decisions. Encouraging a sense of empowerment for patients will ultimately enhance treatment adherence and improve clinical outcomes in GHT.
dc.description.sponsorshipSupported from funds from industry (Novo Nordisk Ltd)
dc.format.mediumElectronic-eCollection
dc.languageeng
dc.publisherFrontiers Media SA
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleShared Decision-Making in Growth Hormone Therapy-Implications for Patient Care.
dc.typeArticle
prism.publicationDate2018
prism.publicationNameFront Endocrinol (Lausanne)
prism.startingPage688
prism.volume9
dc.identifier.doi10.17863/CAM.34027
dcterms.dateAccepted2018-11-02
rioxxterms.versionofrecord10.3389/fendo.2018.00688
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-01
dc.contributor.orcidAcerini, Carlo [0000-0003-2121-5871]
dc.identifier.eissn1664-2392
rioxxterms.typeJournal Article/Review
cam.issuedOnline2018-11-22


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International